GeticoFect RNAiMax Transfection Reagent
Product Ordering Information
Catalog Number | Specification | Price (CNY) |
130201 | 0.75ml | 2,900.00 |
130202 | 1.5ml | 4,200.00 |
130203 | 15ml | 41,200.00 |
1. Product Overview
GeticoFect RNAiMax Transfection Reagent, developed by Getico Scientific(Shanghai) Co., Ltd., is a specialized and advanced transfection reagent tailored for the efficient delivery of small interfering RNA (siRNA) and microRNA (miRNA) into a wide range of eukaryotic cells. This reagent is designed to meet the high - demand requirements of modern RNA interference (RNAi) research, providing researchers with a reliable and powerful tool to manipulate gene expression at the post - transcriptional level.
2. Key Features
2.1 Exceptional Transfection Efficiency
- Optimized for siRNA Delivery: GeticoFect RNAiMax has been engineered with a unique formulation that enables highly efficient encapsulation and delivery of siRNA molecules. In numerous cell lines, it has demonstrated transfection efficiencies of over 90%, even in hard - to - transfect cell types. For example, in the notoriously difficult - to - transfect A549 lung adenocarcinoma cells, GeticoFect RNAiMax has achieved transfection efficiencies as high as 92%, outperforming many traditional transfection reagents. This high efficiency ensures that a large proportion of cells take up the siRNA, leading to effective gene knockdown and minimizing background expression from untransfected cells.
- Low siRNA Concentrations Required: It can achieve significant gene knockdown with remarkably low concentrations of siRNA. In many cases, as little as 1 nM of siRNA is sufficient to achieve high - level gene silencing. This not only reduces the cost of siRNA synthesis but also minimizes potential off - target effects associated with higher siRNA concentrations. By using lower siRNA concentrations, researchers can more precisely target their genes of interest and obtain more accurate results in their RNAi experiments.
2.2 Ultra - Low Cytotoxicity
- Gentle on Cells: The reagent is formulated to be extremely gentle on cells, resulting in ultra - low cytotoxicity. After transfection with GeticoFect RNAiMax, cell viability remains above 95% in a wide variety of cell lines. This is in stark contrast to some traditional transfection reagents that can cause significant cell death and non - specific cellular stress. In long - term RNAi experiments, such as those studying the effects of gene knockdown over several days, the low cytotoxicity of GeticoFect RNAiMax ensures that cell functions are not compromised, allowing for more reliable and physiologically relevant results. For instance, in cell - based assays that require continuous monitoring of cell growth and behavior after gene knockdown, the high cell viability maintained by this reagent enables accurate assessment of the true effects of gene silencing.
2.3 Broad Cell - Type Compatibility
- Versatile Application: GeticoFect RNAiMax is compatible with a broad spectrum of cell types, including common cell lines, stem cells, and primary cells. It has been successfully used in more than 50 different cell lines, ranging from cancer cell lines like HeLa and MCF - 7 to primary fibroblasts and immune cells such as T - lymphocytes. In stem cell research, it has efficiently transfected embryonic stem cells and induced pluripotent stem cells, facilitating studies on gene function during stem cell differentiation and self - renewal. This broad cell - type compatibility makes it a versatile choice for researchers working in diverse fields, from basic cell biology to translational medicine.
2.4 Compatibility with miRNA Transfection
- Effective miRNA Delivery: In addition to its prowess in siRNA transfection, GeticoFect RNAiMax also shows excellent performance in delivering miRNA mimics and antagonists. It can efficiently introduce these miRNA - based molecules into cells, enabling researchers to study miRNA - mediated gene regulation pathways. For example, in experiments aimed at overexpressing a specific miRNA mimic to investigate its role in cell proliferation or apoptosis, GeticoFect RNAiMax has achieved high transfection efficiencies, leading to significant changes in the target gene expression levels associated with the miRNA of interest.
3. Applications
3.1 Gene Function Studies
- Precise Gene Knockdown: In basic research, GeticoFect RNAiMax is an invaluable tool for studying gene function. By efficiently delivering siRNA to knock down specific genes, researchers can observe the resulting phenotypic changes in cells. For example, in a study on the role of a particular gene in cell migration, transfection with GeticoFect RNAiMax - delivered siRNA targeting that gene led to a significant reduction in cell migration ability, as measured by wound - healing assays. This precise gene - knockdown capability allows researchers to establish cause - and - effect relationships between genes and cellular functions, providing insights into normal biological processes and disease mechanisms.
- Pathway Identification: It is also useful for identifying gene - regulatory pathways. Through systematic knockdown of genes within a suspected pathway using GeticoFect RNAiMax, researchers can map out the relationships between different genes and understand how they interact to regulate cellular processes. In cancer research, for instance, this approach has been used to identify key genes in the PI3K - AKT - mTOR pathway, which is often dysregulated in many types of cancers. By knocking down individual genes in this pathway using siRNA delivered by GeticoFect RNAiMax, researchers were able to elucidate the sequence of events and the specific roles of each gene in promoting cancer cell growth and survival.
3.2 Therapeutic Target Validation
- Drug Discovery: In the pharmaceutical industry, GeticoFect RNAiMax plays a crucial role in validating potential therapeutic targets. By knocking down genes that are thought to be involved in disease processes, researchers can determine whether inhibiting these genes could be a viable strategy for drug development. For example, in neurodegenerative disease research, siRNA delivered by GeticoFect RNAiMax has been used to target genes associated with abnormal protein aggregation, such as the APP gene in Alzheimer's disease. If gene knockdown leads to a reduction in the formation of amyloid - beta plaques, it provides evidence that targeting this gene could be a promising therapeutic approach. This helps pharmaceutical companies prioritize their drug - development efforts and increases the likelihood of developing effective drugs.
- RNAi - Based Therapeutics: The reagent is also relevant for the development of RNAi - based therapeutics. As the field of RNAi therapy advances, the ability to efficiently deliver siRNA or miRNA into target cells in vitro is essential for pre - clinical studies. GeticoFect RNAiMax's high transfection efficiency and low cytotoxicity make it an ideal reagent for optimizing the delivery of RNAi agents in cell - based models, which is a critical step towards translating RNAi technology into clinical applications.
3.3 High - Throughput Screening
- Efficient Screening Platform: GeticoFect RNAiMax is well - suited for high - throughput siRNA screening. Its simple and rapid transfection protocol, combined with high transfection efficiency, allows for the efficient transfection of large numbers of siRNA libraries in a short period. In a large - scale screen to identify genes involved in a specific cellular process, such as cell cycle regulation, thousands of different siRNA constructs can be transfected into cells using GeticoFect RNAiMax. The high transfection efficiency ensures that each well in a multi - well plate contains a sufficient number of transfected cells for accurate phenotypic analysis. This enables researchers to quickly identify genes that are essential for the process of interest, accelerating the pace of discovery in functional genomics research.
4. Comparison with Competitors
5. Product Packaging and Pricing
GeticoFect RNAiMax Transfection Reagent is available in convenient and user - friendly packaging. A standard vial contains 0.75 ml of the reagent, which is sufficient for a large number of transfection experiments. The price of GeticoFect RNAiMax is set at 1600 yuan, offering excellent value for its high - performance features. Considering its superior transfection efficiency, low cytotoxicity, broad cell - type compatibility, and effectiveness in miRNA transfection, it provides a cost - effective solution for researchers conducting RNAi - related studies. Whether for small - scale academic research projects or large - scale industrial high - throughput screening, GeticoFect RNAiMax offers a reliable and efficient option without compromising on quality.
In conclusion, GeticoFect RNAiMax Transfection Reagent is a revolutionary product in the field of RNAi transfection. Its exceptional transfection efficiency, ultra - low cytotoxicity, broad cell - type compatibility, and compatibility with miRNA transfection make it an ideal choice for a wide range of research applications, from basic gene function studies to the development of RNAi - based therapeutics.
Language
简体中文 
English 
